Business Context and Reporting Period
This Form 6-K, dated April 17, 2018, reports on a corporate action by Novartis AG (NYSE: NVS), a global healthcare company headquartered in Basel, Switzerland. The filing announces the commencement of a cash tender offer by Novartis AM Merger Corporation, an indirect wholly-owned subsidiary of Novartis, to acquire all outstanding shares of AveXis, Inc. (NASDAQ: AVXS).
Key Financial Metrics
The filing does not provide current period revenue, profit, cash flow, or margin data for Novartis. It references historical 2017 data in the "About Novartis" section:
- 2017 Net Sales: USD 49.1 billion
- 2017 R&D Expenditure: Approximately USD 9.0 billion
- Workforce: Approximately 122,000 full-time-equivalent associates
Regarding the transaction, the filing specifies the following financial terms:
- Offer Price: USD 218.00 per share of AveXis common stock
- Payment Method: Cash, net to the seller, without interest
- Financing Condition: The offer is not subject to a financing condition
Material Changes and Transaction Details
The primary material event is the initiation of the tender offer for AveXis, Inc., pursuant to a Merger Agreement dated April 6, 2018. Key details include:
- Expiration Date: The offer expires at 12:00 midnight, New York City time, on May 14, 2018, unless extended.
- Recommendation: The AveXis board of directors has recommended that stockholders accept the offer.
- Regulatory Filings: Novartis filed a Tender Offer Statement on Schedule TO, and AveXis filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC on April 17, 2018.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the potential completion of the acquisition. Management highlights several risks and contingencies that could prevent the transaction from closing:
- Closing Conditions: The offer is subject to customary conditions, including the tender of at least a majority of outstanding AveXis shares on a fully diluted basis.
- Regulatory Approval: Completion is contingent upon the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Legal and Regulatory Risks: Potential delays or actions by regulators, failures to meet closing conditions, and uncertainties regarding legal proceedings.
- No Guarantee: There is no guarantee the acquisition will be completed, completed as proposed, or completed at any particular time.
Investor Verification Checklist
- Verify the full terms and conditions in the Tender Offer Statement on Schedule TO filed with the SEC.
- Confirm the recommendation of the AveXis board of directors in the Schedule 14D-9 filing.
- Monitor the status of the Hart-Scott-Rodino waiting period and any other regulatory approvals required.
- Check for any public announcements regarding extensions of the offer expiration date (May 14, 2018).
- Review Novartis AG's current Form 20-F for a comprehensive list of risk factors affecting the company and this transaction.